The human monoclonal antibody golimumab (Simponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year ...

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, ...

The benefits of golimumab reported at 24 weeks in patients with psoriatic arthritis persisted at 2 years, according to the results of a 104-week open-label extension of the randomized GO-REVEAL study.

Patients treated with golimumab had higher C-peptide levels at week 52 compared to placebo. “This was statistically significant, thus the study met its primary goal,” Quattrin says. “In fact, 41% of ...

The Golimumab -- A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL) trial involved 405 adults with psoriatic ...

Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each single-dose vial contains 50 mg of Simponi Aria per 4 mL of solution.

Golimumab targets and neutralizes both the soluble and membrane-bound forms of TNF-alpha. Centocor discovered golimumab and has exclusive marketing rights to the product in the United States.

A biosimilar for golimumab has demonstrated therapeutic equivalence in rheumatoid arthritis, with no clinically meaningful safety differences, according to a press release from the manufacturer.

Golimumab is a tumor necrosis factor (TNF) blocker, prescribed for rheumatoid arthritis, ankylosing spondylitis, moderate to severe ulcerative colitis either alone or with other medications.

4 Consideration of the evidence. 4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of golimumab, having considered evidence on the nature of psoriatic ...

Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha). Elevated TNF alpha levels have been implicated in the pathophysiology of several chronic inflammatory ...

The Committee considered the evidence on the clinical effectiveness of golimumab in combination with methotrexate and noted that the manufacturer's submission considered golimumab at 2 positions in ...